1-20 of 243
Thierry Façon
Close
Sort by
Journal Articles

How I treat multiple myeloma in geriatric patients

Thierry Facon, Xavier Leleu, Salomon Manier
Journal: Blood
Blood (2024) 143 (3): 224–232.
https://doi.org/10.1182/blood.2022017635
Published: 2024
Journal Articles

The Impact of Isatuximab Regimens on Hypogammaglobulinemia Occurrence, Recovery, and Associated Infections in Patients with Relapsed/Refractory Multiple Myeloma

Cesar Rodriguez, Aurore Perrot, Paul G. Richardson, Thierry Facon, Ivan Spicka, Albert Oriol, Kenshi Suzuki, Edvan Crusoe, Ajai Chari, Nicole Armstrong, Christina Tekle, Marie-Laure Risse, Thomas Martin, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2023-179925
Published: 2023
Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Arthur Bobin, Cyrille Hulin, Jerome Lambert, Aurore Perrot, Salomon Manier, Lydia Montes, Arnaud Jaccard, Lionel Karlin, Pascal Godmer, Denis Caillot, Thomas Chalopin, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Jacques Delaunay, Claire Dingremont, Alberto Santagostino, Mamoun Dib, Margaret Macro, Mourad Tiab, Kamel Laribi, Emmanuelle Bourgeois Petit, Claire Calmettes, Frederique Orsini Piocelle, Benoit Bareau, Reza Tabrizi, Laure Vincent, Mohamad Mohty, Cyrille Touzeau, Jill Corre, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6741.
https://doi.org/10.1182/blood-2023-185699
Published: 2023
Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Arthur Bobin, Salomon Manier, Joe De Keizer, Cyrille Hulin, Lionel Karlin, Denis Caillot, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoit Bareau, Karim Belhadj Merzoug, Lotfi Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Helene Demarquette, Pierre Feugier, Cécile Sonntag, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Petillon, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6724.
https://doi.org/10.1182/blood-2023-186599
Published: 2023
Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Sarah Cayla, Benoit Ferment, Noemie Bigot, Denis Caillot, Ingrid Lafon, Lionel Karlin, Anne Lazareth, Cyrille Touzeau, Xavier Leleu, Niels Moya, Stephanie Harel, Aurore Perrot, Pierre Bories, Laure Vincent, Sylvain Lamure, Mohamad Mohty, Florent Malard, Salomon Manier, Ibrahim Yakoub-Agha, Anne-Marie Stoppa, Gabriel Brisou, Olivier Decaux, Roch Houot, Steven Le Gouill, Jerome Lambert, Thierry Facon, Herve Avet Loiseau, Philippe Moreau, Bertrand Arnulf
Journal: Blood
Blood (2023) 142 (Supplement 1): 2139.
https://doi.org/10.1182/blood-2023-188655
Published: 2023
Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko, Iva Lelios, Jan Attig, Nassim Sleiman, Domenico Lazzaro, Emilie Schindler, Jan Eckmann, Pablo Umana, Wolfgang Jacob, Meike Schneider, Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Martin Hutchings, Caroline Hasselbalch Riley, Ann-Marie E Bröske
Journal: Blood
Blood (2022) 140 (Supplement 1): 10137–10139.
https://doi.org/10.1182/blood-2022-158146
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Thierry Facon, Shaji K Kumar, Katja Weisel, Saad Usmani, Philippe Moreau, Torben Plesner, Robert Z. Orlowski, Nizar Jacques Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Robin Carson, Fredrik Borgsten, Hartmut Goldschmidt
Journal: Blood
Blood (2022) 140 (Supplement 1): 10133–10136.
https://doi.org/10.1182/blood-2022-163555
Published: 2022
Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Arthur Bobin, Jerome Lambert, Aurore Perrot, Salomon Manier, Lydia Montes, Arnaud Jaccard, Lionel Karlin, Pascal Godmer, Denis Caillot, Cyrille Hulin, Thomas Chalopin, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Dingremont, Alberto Santagostino, Mamoun Dib, Margaret Macro, Mourad Tiab, Kamel Laribi, Emmanuelle Bourgeois-Petit, Claire Calmettes, Frederique Orsini, Reza Tabrizi, Laure Vincent, Mohamad Mohty, Cyrille Touzeau, Jill Corre, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4423–4425.
https://doi.org/10.1182/blood-2022-168742
Published: 2022
Journal Articles

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo-Stella, Rita Mazza, Salomon Manier, Thierry Facon, Sung-Soo Yoon, Youngil Koh, Simon J Harrison, Jeremy Er, Antonio Pinto, Francesco Volzone, Giulia Perrone, Paolo Corradini, Titouan Cazaubiel, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, Enrique M. Ocio, Carmen Maria Montes Gaisan, Rakesh Popat, Sarah Leong, Fritz Offner, Paula Rodriguez Otero, Ana Alfonso-Pierola, Ann-Marie E Bröske, Iryna Dekhtiarenko, Hans-Joachim Helms, Sara Belli, Eva Rossmann, Tanja Fauti, Jan Eckmann, Tom Moore, Meike Schneider, Wolfgang Jacob, Martin Weisser, Martin Hutchings, Caroline Hasselbalch Riley
Journal: Blood
Blood (2022) 140 (Supplement 1): 397–399.
https://doi.org/10.1182/blood-2022-157988
Published: 2022
Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin
Journal: Blood
Blood (2022) 140 (Supplement 1): 1820–1822.
https://doi.org/10.1182/blood-2022-159105
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial

Salomon Manier, Jill Corre, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian-Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini-Piocelle, Mamoun Dib, Margaret Macro, Laurence Sanhes, Aurore Perrot, Jean Yves Mary, Jerome Lambert, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon
Journal: Blood
Blood (2022) 140 (Supplement 1): 1369–1370.
https://doi.org/10.1182/blood-2022-159933
Published: 2022
Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Benoit Ferment, Jérôme Lambert, Denis Caillot, Ingrid Lafon, Lionel Karlin, Anne Lazareth, Cyrille Touzeau, Xavier Leleu, Niels Moya, Stephanie Harel, Aurore Perrot, Pierre Bories, Laure Vincent, Sylvain Lamure, Mohamad Mohty, Florent Malard, Salomon Manier, Ibrahim Yakoub-Agha, Anne-Marie Stoppa, Gabriel Brisou, Olivier Decaux, Roch Houot, Steven Le Gouill, Thierry Facon, Hervé Avet-Loiseau, Philippe Moreau, Bertrand Arnulf
Journal: Blood
Blood (2022) 140 (Supplement 1): 4668–4670.
https://doi.org/10.1182/blood-2022-162682
Published: 2022
Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Clinical Trials & Observations
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal
Journal: Blood
Blood (2022) 139 (18): 2747–2757.
https://doi.org/10.1182/blood.2021014635
Published: 2022
Includes: Supplemental data
Journal Articles

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Clinical Trials & Observations
Michele Cavo, Jesus San-Miguel, Saad Z. Usmani, Katja Weisel, Meletios A. Dimopoulos, Hervé Avet-Loiseau, Bruno Paiva, Nizar J. Bahlis, Torben Plesner, Vania Hungria, Philippe Moreau, Maria-Victoria Mateos, Aurore Perrot, Shinsuke Iida, Thierry Facon, Shaji Kumar, Niels W. C. J. van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec, Rachel Kobos, Steven Sun, Mia Qi, Nikhil Munshi
Journal: Blood
Blood (2022) 139 (6): 835–844.
https://doi.org/10.1182/blood.2021011101
Published: 2022
Includes: Supplemental data
Journal Articles

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Clinical Trials & Observations
Jesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, María-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Journal: Blood
Blood (2022) 139 (4): 492–501.
https://doi.org/10.1182/blood.2020010439
Published: 2022
Includes: Supplemental data
Journal Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 118.
https://doi.org/10.1182/blood-2021-144914
Published: 2021
Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Sundar Jagannath, Thierry Facon, Ashraf Z. Badros, Moshe Levy, Philippe Moreau, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Iryna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Chris P. Venner, Mamta Garg, Mercedes Gironella Mesa, Artur Jurczyszyn, Tadeusz Robak, Monica Galli, Craig Thomas Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don Stevens, Supratik Basu, Anna Marina Liberati, Hang Quach, Veselina S Goranova Marinova, Jelena Sreten Bila, Eirini Katodritou, Andrew DeCastro, Yi Chai, Dane R. Van Domelen, Moran Mishal, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sebastian Grosicki, Paul G. Richardson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3793.
https://doi.org/10.1182/blood-2021-146003
Published: 2021